StockData
CG Oncology, Inc. logo

CG Oncology, Inc. (CGON) stock

CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$84.78+10.38 (+13.95%)

Close on Nov 16, 2026Market cap $7.51BP/E –Yield –

CG Oncology ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

CG Oncology's ebitda for the twelve months ending Sep 30, 2026 was -$261.04M. For fiscal 2025 it was -$189.33M.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$189.33M–
FY2024Dec 31, 2024-$114.63M–
FY2023Dec 31, 2023-$55.43M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$62.09M–
Q2 FY2026Jun 30, 2026-$85.55M–
Q1 FY2026Mar 31, 2026-$65.55M–
Q4 FY2025Dec 31, 2025-$47.85M–
Q3 FY2025Sep 30, 2025-$50.71M–
Q2 FY2025Jun 30, 2025-$48.59M–
Q1 FY2025Mar 31, 2025-$42.18M–
Q4 FY2024Dec 31, 2024-$38.05M–
Q3 FY2024Sep 30, 2024-$28.27M–
Q2 FY2024Jun 30, 2024-$25.85M–
Q1 FY2024Mar 31, 2024-$22.47M–
Q4 FY2023Dec 31, 2023-$19.35M–
Q3 FY2023Sep 30, 2023-$14.04M–
Q2 FY2023Jun 30, 2023-$12.32M–
Q1 FY2023Mar 31, 2023-$9.72M–

More CG Oncology figures

See a number that looks wrong?